BioNTech said its CTLA-4 antibody gotistobart nearly doubled survival times in a lung cancer population studied in newly reported evidence. The company reported that previously treated patients receiving gotistobart lived 8.5 months longer than a control group, building a stronger case for ongoing development of the therapy. CTLA-4 blockade has proven immunogenic in multiple tumor types, but translating survival gains into consistent clinical positioning is often challenging. BioNTech’s update therefore matters for investors and competitors deciding whether to expand CTLA-4-based strategies beyond earlier benchmarks. The reported survival improvement also strengthens the rationale for combinability and sequencing discussions in the lung cancer market, where CTLA-4 approaches must compete with PD-1 backbones and antibody-drug conjugate options.